phase 1
ii 1
study 1
tlr 1
agonist 1
iss 1
rituximab 1
patients 1
relapsed 1
refractory 1
follicular 1
lymphoma 2
antibody 1
immunomodulatory 1
agents 1
treatment 1
indolent 1
nonhodgkins 1
